Detalhe da pesquisa
1.
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.
Clin Genitourin Cancer
; 15(1): 31-41.e4, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27916626